Pierre Dodion joined Innate Pharma in September 2014. He has 25 years of experience in Medical affairs in the pharmaceutical industry having worked at Pfizer (2006-2008), Novartis (2002-2006) and Aventis (1996-2002). He contributed to the development, approval and launch of several drugs, including sunitinib (Sutent®, kidney cancer and GIST) and letrozole (Femara®, breast cancer).
In 2007, Pierre Dodion joined ARIAD Pharmaceuticals (Nasdaq: ARIA), first as SVP and Chief Medical Officer, then as SVP Corporate Development and Operations. He played a major role in the expansion of ARIAD, notably in Europe. He contributed to two development programs in oncology: ridaforolimus (licensed to Merck) and ponatinib (marketed by ARIAD Pharmaceuticals as Iclusig®).
Pierre Dodion is a medical doctor, with a specialization degree in Oncology from the Free University of Brussels, Belgium and a MBA degree from the Saint Joseph University of Philadelphia, PA.